HOME > MARKETS > MARKET COMMENTARY
  MARKET COMMENTARY
EQUITY
Alembic Pharma moves up on getting USFDA’s final approval for Prucalopride Tablets
Jul-28-2026

Alembic Pharmaceuticals is currently trading at Rs. 818.75, up by 4.30 points or 0.53% from its previous closing of Rs. 814.45 on the BSE.

The scrip opened at Rs. 814.45 and has touched a high and low of Rs. 828.70 and Rs. 812.90 respectively. So far 6493 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1024.70 on 28-Jul-2025 and a 52 week low of Rs. 635.30 on 23-Mar-2026.

Last one week high and low of the scrip stood at Rs. 841.35 and Rs. 790.35 respectively. The current market cap of the company is Rs. 16101.47 crore.

The promoters holding in the company stood at 69.87%, while Institutions and Non-Institutions held 20.12% and 10.01% respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Prucalopride Tablets, 1 mg and 2 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA Inc. Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults. 

Prucalopride Tablets, 1 mg and 2 mg, have an estimated market size of $100 million for twelve months ending March 2026 according to IQVIA. Alembic has a cumulative total of 245 ANDA approvals (225 final approvals and 20 tentative approvals) from USFDA.

Alembic Pharmaceuticals is involved in manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities.

  RELATED NEWS >>